Supplemental Table S5. Sensitivity Analysis of the Meta-Analysis in Patients with Poorly Differentiated Thyroid Carcinoma

Study excluded	Random-effects model		Heterogeneity	
	Proportion, %	95% CI	I^2, %	P value
DFS				
Bhargav et al. (2010) [4]	50.6	43.8–57.4	54	0.01
Gnemmi et al. (2014) [6]	48.5	41.1–56.0	58	<0.01
Yu et al. (2017) [9]	49.4	41.8–57.0	62	<0.01
de la Fouchardiere et al. (2018) [10]	50.0	41.9–58.0	61	<0.01
Nunes da Silva et al. (2018) [12]	48.1	41.2–55.1	56	<0.01
Bichoo et al. (2019) [13]	50.4	43.2–57.6	59	<0.01
Akaishi et al. (2019) [14]	49.9	42.2–57.6	61	<0.01
Wong et al. (2019) [15]	48.7	41.2–56.3	60	<0.01
Panchangam et al. (2022) [17]	50.0	42.4–57.6	61	<0.01
Xu et al. (Turin) (2022) [18]	50.7	43.4–58.0	51	0.02
Xu et al. (DHGTC) (2022) [18]	49.2	41.0–57.4	60	<0.01
Jeong et al. (2023) [20] (Turin)	48.2	41.4–55.0	56	<0.01
Jeong et al. (2023) [20] (DHGTC)	48.0	41.6–54.6	54	0.01
OS				
Lin et al. (2007) [1]	74.3	66.5–80.7	57	<0.01
Jung et al. (2007) [2]	74.1	66.4–80.6	57	<0.01
Asioli et al. (2010) [3]	74.1	66.2–80.6	57	<0.01
Bhargav et al. (2010) [4]	74.6	67.4–80.6	53	<0.01
Hod et al. (2013) [5]	73.4	65.9–79.8	56	<0.01
Gnemmi et al. (2014) [6]	73.9	66.1–80.4	57	<0.01
Lee et al. (2016) [7]	74.3	66.6–80.7	57	<0.01
Skansing et al. (2017) [8]	74.1	66.3–80.6	57	<0.01
Yu et al. (2017) [9]	73.4	65.9–79.7	55	<0.01
de la Fouchardiere et al. (2018) [10]	74.0	66.2–80.6	57	<0.01
Ito et al. (2018) [11]	73.7	66.0–80.2	56	<0.01
Nunes da Silva et al. (2018) [12]	73.8	66.0–80.3	56	<0.01
Bichoo et al. (2019) [13]	74.6	68.2–80.1	42	0.02
Akaishi et al. (2019) [14]	72.0	65.6–77.6	50	<0.01
Wong et al. (2019) [15]	73.2	65.7–79.6	53	<0.01
Kersting et al. (2021) [16]	74.5	67.0–80.8	54	<0.01
Panchangam et al. (2022) [17]	74.6	67.8–80.5	48	<0.01
Xu et al. (Turin) (2022) [18]	74.3	66.5–80.8	57	<0.01
Xu et al. (DHGTC) (2022) [18]	74.2	66.3–80.7	57	<0.01
Gubbiotti et al. (2023) [19] (Turin)	73.3	65.7–79.8	52	<0.01
Jeong et al. (2023) [20] (Turin)	72.0	65.7–77.6	57	<0.01
Jeong et al. (2023) [20] (DHGTC)	72.5	65.7–78.3	57	<0.01

CI, confidence interval; DFS, disease-free survival; DHGTC, differentiated high-grade thyroid carcinoma; OS, overall survival.